EnteroBiotix Completes £27m Financing Round to Advance Clinical Trials

Released: Thursday 4th April 2024

EnteroBiotix Limited, a clinical-stage biotechnology company focussed on developing best-in-class full-spectrum microbiome therapeutics, today announced that the Company has completed its £27m ($34m USD) funding round, supported by new and existing investors.

For full details please click here.

View all News